3647 results for «604»

Filter By

3647 results

Coronary interventions: first-in-man and novel devices

20 May 2026 – From EuroPCR 2026

Explore pioneering advancements in coronary interventions with first-in-man and novel devices. This session presents groundbreaking studies including cryotherapy for vulnerable plaques, a novel intravascular crossing system for coronary CTOs, sirolimus-coated retrievable scaffold therapy for in-stent restenosis, real-time intravascular photoacoustic imaging of lipid-rich plaques, and the inaugural...

Complex left main patients and PCI

20 May 2026 – From EuroPCR 2026

This session addressed the complexities of left main PCI, focusing on managing hemodynamic uncertainty in high-risk interventions, advanced techniques such as ultra-low contrast rota-tripsy PCI, precise stent positioning, and pragmatic approaches to CHIP cases, emphasizing contrast-sparing strategies and best practice balancing.

TAVI for aortic regurgitation

20 May 2026 – From EuroPCR 2026

This session highlights innovative transcatheter aortic valve implantation (TAVI) approaches for treating aortic regurgitation, focusing on off-label uses and complex cases. It features high-risk patient interventions, including nonagenarian patients, and strategies to manage severe non-calcific native valve regurgitation with balloon-expandable valves.

Imaging and physiology integration to guided PCI

20 May 2026 – From EuroPCR 2026

Discover the integration of imaging and physiological assessment in guiding percutaneous coronary intervention (PCI). This session highlights the use of multimodality diagnostics, including invasive and non-invasive techniques, to improve planning, strategy, and management of complex coronary lesions.

Which AF patients may benefit from LAA closure?

02 Jul 2026

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Martin W. Bergmann

Author

Martin W. Bergmann
Which AF patients may benefit from LAA Closure?

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

Future directions of drug-coated balloon angioplasty

06 Feb 2025

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Dr. F. Alfonso

Author

Fernando Alfonso
Javier Cuesta

Author

Javier Cuesta
Future directions of drug-coated balloon angioplasty
Didn’t find what you were looking for?